TY - JOUR
T1 - An official American thoracic society research statement
T2 - Current challenges facing research and therapeutic advances in airway remodeling
AU - Prakash, Y. S.
AU - Halayko, Andrew J.
AU - Gosens, Reinoud
AU - Panettieri, Reynold A.
AU - Camoretti-Mercado, Blanca
AU - Penn, Raymond B.
AU - Aiyar, Ram
AU - Ammit, Alaina
AU - Berkman, Neville
AU - Bond, Richard
AU - Brown, Robert
AU - Boulet, Louis
AU - Burgess, Janette
AU - Chung, Kian Fan
AU - Debley, Jason
AU - Deshpande, Deepak
AU - Freemer, Michelle
AU - Glass, Mitchell
AU - Haczku, Angela
AU - Holgate, Stephen
AU - Irvin, Charles
AU - Jacoby, David
AU - Johnson, Jill
AU - Meurs, Hermann
AU - Murphy, Thomas
AU - Murthy, Mahadev
AU - Noel, Patricia
AU - O'Byrne, Paul
AU - Pabelick, Christina
AU - Pera, Tonio
AU - Poynter, Matthew
AU - Robinson, Gary
AU - Saglani, Sejal
AU - Solway, Julian
AU - Stewart, Alastair
AU - Tliba, Omar
AU - Togias, Alkis
AU - Woodruff, Prescott
PY - 2017/1/15
Y1 - 2017/1/15
N2 - Background: Airway remodeling (AR) is a prominent feature of asthma and other obstructive lung diseases that is minimally affected by current treatments. The goals of this Official American Thoracic Society (ATS) Research Statement are to discuss the scientific, technological, economic, and regulatory issues that deter progress of AR research and development of therapeutics targeting AR and to propose approaches and solutions to these specific problems. This Statement is not intended to provide clinical practice recommendations on any disease in which AR is observed and/or plays a role. Methods: An international multidisciplinary group from within academia, industry, and the National Institutes of Health, with expertise in multimodal approaches to the study of airway structure and function, pulmonary research and clinical practice in obstructive lung disease, and drug discovery platforms was invited to participate in one internet-based and one face-to-face meeting to address the above-stated goals. Although the majority of the analysis related to AR was in asthma, AR in other diseases was also discussed and considered in the recommendations. A literature search of PubMed was performed to support conclusions. The search was not a systematic review of the evidence. Results: Multiple conceptual, logistical, economic, and regulatory deterrents were identified that limit the performance of AR research and impede accelerated, intensive development of AR-focused therapeutics. Complementary solutions that leverage expertise of academia and industry were proposed to address them. Conclusions: To date, numerous factors related to the intrinsic difficulty in performing AR research, and economic forces that are disincentives for the pursuit of AR treatments, have thwarted the ability to understandARpathology and mechanisms and to address it clinically. This ATS Research Statement identifies potential solutions for each of these factors and emphasizes the importance of educating the global research community as to the extent of the problem as a critical first step in developing effective strategies for: (1) increasing the extent and impact of AR research and (2) developing, testing, and ultimately improving drugs targeting AR.
AB - Background: Airway remodeling (AR) is a prominent feature of asthma and other obstructive lung diseases that is minimally affected by current treatments. The goals of this Official American Thoracic Society (ATS) Research Statement are to discuss the scientific, technological, economic, and regulatory issues that deter progress of AR research and development of therapeutics targeting AR and to propose approaches and solutions to these specific problems. This Statement is not intended to provide clinical practice recommendations on any disease in which AR is observed and/or plays a role. Methods: An international multidisciplinary group from within academia, industry, and the National Institutes of Health, with expertise in multimodal approaches to the study of airway structure and function, pulmonary research and clinical practice in obstructive lung disease, and drug discovery platforms was invited to participate in one internet-based and one face-to-face meeting to address the above-stated goals. Although the majority of the analysis related to AR was in asthma, AR in other diseases was also discussed and considered in the recommendations. A literature search of PubMed was performed to support conclusions. The search was not a systematic review of the evidence. Results: Multiple conceptual, logistical, economic, and regulatory deterrents were identified that limit the performance of AR research and impede accelerated, intensive development of AR-focused therapeutics. Complementary solutions that leverage expertise of academia and industry were proposed to address them. Conclusions: To date, numerous factors related to the intrinsic difficulty in performing AR research, and economic forces that are disincentives for the pursuit of AR treatments, have thwarted the ability to understandARpathology and mechanisms and to address it clinically. This ATS Research Statement identifies potential solutions for each of these factors and emphasizes the importance of educating the global research community as to the extent of the problem as a critical first step in developing effective strategies for: (1) increasing the extent and impact of AR research and (2) developing, testing, and ultimately improving drugs targeting AR.
UR - http://www.scopus.com/inward/record.url?scp=85009787260&partnerID=8YFLogxK
UR - https://www.atsjournals.org/doi/10.1164/rccm.201611-2248ST
U2 - 10.1164/rccm.201611-2248ST
DO - 10.1164/rccm.201611-2248ST
M3 - Review article
C2 - 28084822
AN - SCOPUS:85009787260
SN - 1073-449X
VL - 195
SP - e4-e19
JO - American Journal of Respiratory and Critical Care Medicine
JF - American Journal of Respiratory and Critical Care Medicine
IS - 2
ER -